Pulmonary fibrosis is a condition where scarring develops in the lungs, making it increasingly difficult to breathe and reducing the quality of daily life. The approach to treating this disease focuses on managing symptoms, slowing down the scarring process, and helping people live as comfortably as possible despite the condition. Treatment options range from medications approved by medical authorities to innovative therapies being tested in clinical trials around the world.

Understanding the Goals of Treatment for Pulmonary Fibrosis

When someone receives a diagnosis of pulmonary fibrosis, understanding what treatment can and cannot achieve becomes essential. The scarring that has already formed in the lungs cannot be reversed or repaired^[1]. This reality shapes the entire treatment approach. Instead of aiming for a cure, treatment focuses on slowing the progression of scarring, easing troublesome symptoms like breathlessness and cough, and improving the person’s ability to engage in daily activities^[2].

The treatment plan varies greatly depending on the type of pulmonary fibrosis diagnosed, how far the disease has progressed, and individual patient characteristics such as age, other health conditions, and personal preferences. Some people may remain relatively stable for many years with appropriate treatment, while others may experience faster progression^[1]. Medical societies and expert panels have developed guidelines for standard treatments that have proven helpful. At the same time, researchers continue to explore new therapies through clinical trials, offering hope for better options in the future^[11].

Treatment decisions are made through collaboration between the patient and a healthcare team that may include pulmonologists (doctors specializing in lung diseases), nurses, physical therapists, dietitians, and other specialists. This team approach ensures that all aspects of living with pulmonary fibrosis receive attention, not just the lung condition itself.

Standard Medical Treatment Approaches

The foundation of treating pulmonary fibrosis consists of therapies that have been studied extensively and approved by regulatory authorities. These treatments form the backbone of care for many patients.

Antifibrotic Medications

Two medications have become central to the treatment of idiopathic pulmonary fibrosis (IPF), the most common form of this disease where the cause remains unknown. These are pirfenidone and nintedanib^[15]. Both drugs belong to a class called antifibrotics, which means they work to slow down the formation of scar tissue in the lungs.

Pirfenidone is thought to have both anti-inflammatory and antifibrotic properties. Clinical trials have shown that it can slow the decline in lung function in people with mild to moderate idiopathic pulmonary fibrosis. The medication is taken by mouth three times a day^[15]. Common side effects include sensitivity to sunlight, nausea, and stomach upset. Patients taking pirfenidone are advised to avoid direct sunlight and use sunscreen, as the medication can make skin more susceptible to burning^[11].

Nintedanib works by blocking multiple pathways involved in the scarring process. It has been approved not only for idiopathic pulmonary fibrosis but also for other progressive forms of lung fibrosis, including scleroderma-associated interstitial lung disease. Clinical trials demonstrated that nintedanib slows the rate of lung function decline. This medication is taken by mouth twice daily. Side effects frequently include diarrhea, nausea, and liver enzyme changes, which require monitoring through blood tests^[15].

Neither pirfenidone nor nintedanib stops the disease completely or reverses existing damage, but they represent significant progress in managing a condition that previously had no approved treatments. The duration of therapy typically continues indefinitely as long as the medication is tolerated and appears beneficial^[16].

Immunosuppressive Medications

For certain types of pulmonary fibrosis associated with autoimmune diseases or inflammatory conditions, medications that suppress the immune system may be recommended. These include drugs like corticosteroids (such as prednisone), azathioprine, mycophenolate, and others^[2]. The logic behind using these medications stems from understanding that in some forms of lung disease, the immune system contributes to inflammation that eventually leads to scarring.

Corticosteroids work by reducing inflammation throughout the body. However, long-term use carries significant side effects including weight gain, increased blood sugar, bone weakening, and increased infection risk. For types of pulmonary fibrosis where inflammation plays a major role, such as certain forms of hypersensitivity pneumonitis or autoimmune-related lung disease, these medications can be important for controlling disease activity^[6].

Other immunosuppressive drugs like mycophenolate or azathioprine may be used in combination with corticosteroids or as alternatives. Recent research has explored the use of tocilizumab, a biologic medication that blocks inflammatory signals, specifically for scleroderma-associated lung disease. Clinical trials showed it could reduce the rate of lung function decline in this specific condition^[15].

Supplemental Oxygen Therapy

As pulmonary fibrosis progresses, the scarred lung tissue becomes less efficient at transferring oxygen from the air into the bloodstream. This leads to low oxygen levels in the blood, a condition called hypoxemia^[2]. Supplemental oxygen therapy addresses this problem by providing oxygen-enriched air to breathe, ensuring that the body receives adequate oxygen despite impaired lung function.

Oxygen therapy can improve symptoms significantly. People often feel less breathless, more energetic, and better able to engage in activities. Research has shown that in people with low oxygen levels, supplemental oxygen can increase life expectancy and improve overall health^[18]. Oxygen may be needed only during physical activity and sleep at first, but as disease progresses, some people require oxygen continuously.

Modern oxygen delivery systems have become more portable and less cumbersome than in the past. Options include compressed oxygen cylinders, liquid oxygen systems, and oxygen concentrators that extract oxygen from room air. Portable units allow many people to continue traveling and maintaining social connections^[2].

Pulmonary Rehabilitation

Pulmonary rehabilitation is a comprehensive program designed to help people with lung disease improve their physical condition and learn to manage their symptoms more effectively. These programs typically involve exercise training, education about the disease, nutritional counseling, and psychological support^[11].

The exercise component is carefully tailored to each person’s abilities and gradually increases in intensity. This might include walking, cycling, or strength training. Although it may seem counterintuitive to exercise when breathing is difficult, appropriate physical activity actually helps strengthen the muscles involved in breathing and improves overall endurance. People who complete pulmonary rehabilitation programs often report improved quality of life and reduced breathlessness during daily activities^[12].

Education sessions teach breathing techniques that can help during periods of breathlessness, energy conservation strategies for daily tasks, and how to recognize signs of worsening disease. Support from others facing similar challenges and from healthcare professionals provides emotional benefits that are just as important as the physical improvements^[19].

Lung Transplantation

For carefully selected patients with advanced pulmonary fibrosis, lung transplantation represents the only treatment proven to extend life^[16]. This major surgical procedure involves replacing one or both diseased lungs with healthy lungs from a deceased donor.

Not everyone with pulmonary fibrosis is a candidate for transplantation. The selection process is rigorous and considers factors such as age, other health conditions, social support, and ability to comply with complex post-transplant care. Most transplant centers have age limits, typically around 65 to 70 years old, though this varies^[11].

Lung transplantation carries significant risks including surgical complications, rejection of the transplanted organ, and infections due to the immunosuppressive medications required to prevent rejection. However, for appropriate candidates, it can dramatically improve quality of life and extend survival. The shortage of donor organs means that waiting times can be long, and not all listed patients receive a transplant. Early referral to a transplant center is important for people who might be candidates, as the evaluation process takes time^[16].

Treatment in Clinical Trials: Exploring Future Options

While current approved treatments represent progress, they are not adequate for all patients, and the search for better therapies continues actively. Clinical trials test new medications and approaches that may become standard treatments in the future.

Understanding Clinical Trial Phases

Clinical trials proceed through distinct phases, each designed to answer specific questions. Phase I trials involve small numbers of participants and primarily assess safety, determine appropriate dosing, and identify side effects. Phase II trials involve larger groups and begin to evaluate whether the treatment actually works for the intended purpose while continuing to monitor safety. Phase III trials are large studies that compare the new treatment against current standard treatments or placebo to definitively establish efficacy and safety^[17]. Only after successfully completing these phases can a treatment be submitted for regulatory approval.

Innovative Molecules and Mechanisms Being Tested

Researchers are investigating numerous biological pathways involved in pulmonary fibrosis. Understanding that excessive scarring results from dysregulation of normal wound healing processes, scientists have identified various molecular targets that might be interrupted to slow or prevent fibrosis^[5].

One area of investigation involves proteins called interleukins and transforming growth factor-beta (TGF-β), which play central roles in inflammation and scar formation. Experimental drugs that block these proteins are being tested to see if preventing their action can reduce lung scarring. For example, medications targeting IL-13 and TGF-β pathways are in various stages of clinical testing^[5].

Another promising area involves medications that affect cellular processes related to aging and stress responses in lung cells. Research has shown that in idiopathic pulmonary fibrosis, lung cells may age prematurely and respond abnormally to injury, leading to scarring rather than proper healing. Therapies targeting these cellular mechanisms are being explored^[6].

Pentraxin proteins, which are involved in immune regulation and tissue repair, represent another therapeutic target being investigated. Studies are examining whether modulating pentraxin activity could beneficially affect the scarring process^[16].

Gene Therapy and Regenerative Approaches

Cutting-edge research is exploring whether gene therapy or stem cell approaches might offer new treatment possibilities. Some researchers are investigating whether delivering genes that produce anti-scarring proteins directly to lung tissue could slow fibrosis. Others are studying whether stem cells might help regenerate damaged lung tissue or modulate the inflammatory response that leads to scarring^[17].

These approaches remain in early research phases, and it will take years to determine whether they are safe and effective. However, they represent the kind of innovative thinking that could eventually transform treatment.

Repurposing Existing Medications

Not all clinical trials involve brand-new molecules. Some studies test medications already approved for other conditions to see if they might help pulmonary fibrosis. This approach, called drug repurposing, can sometimes speed the path to new treatments since safety information already exists. Various medications originally developed for other purposes are being evaluated in pulmonary fibrosis trials^[17].

Combination Therapies

Since pulmonary fibrosis involves multiple biological processes going wrong simultaneously, some researchers are testing whether combining medications that work through different mechanisms might be more effective than single drugs alone. Trials are examining combinations of antifibrotic medications with anti-inflammatory drugs or other agents to see if targeting multiple pathways provides greater benefit^[16].

Geographic Availability of Clinical Trials

Clinical trials for pulmonary fibrosis are conducted at medical centers around the world, including locations in the United States, Europe, and other regions. Major academic medical centers and specialized pulmonary fibrosis programs often participate in multiple trials. Organizations like the Pulmonary Fibrosis Foundation maintain databases of ongoing clinical trials that patients and their doctors can search to find studies for which they might be eligible^[17].

Eligibility for specific trials depends on many factors including the type and severity of pulmonary fibrosis, age, other health conditions, and medications being taken. Some trials specifically seek people newly diagnosed, while others focus on those with more advanced disease. The trial protocols define these criteria carefully to ensure that the study can answer its intended questions while keeping participants as safe as possible.

Most common treatment methods

• Antifibrotic medications
  • Pirfenidone – taken orally three times daily to slow lung function decline in idiopathic pulmonary fibrosis
  • Nintedanib – taken orally twice daily, approved for idiopathic pulmonary fibrosis and progressive fibrosing lung diseases
• Immunosuppressive therapy
  • Corticosteroids like prednisone to reduce inflammation in certain types of pulmonary fibrosis
  • Mycophenolate and azathioprine for autoimmune-related lung disease
  • Tocilizumab for scleroderma-associated interstitial lung disease
• Oxygen therapy
  • Supplemental oxygen delivered through nasal cannula to maintain adequate blood oxygen levels
  • Portable oxygen systems to maintain activity and quality of life
  • Continuous oxygen for advanced disease
• Pulmonary rehabilitation
  • Supervised exercise programs tailored to individual abilities
  • Breathing technique training and education
  • Nutritional counseling and psychological support
• Lung transplantation
  • Single or bilateral lung transplant for selected patients with advanced disease
  • The only treatment proven to extend life in pulmonary fibrosis
• Symptom management
  • Cough suppressants and expectorants to manage persistent cough
  • Treatment for gastroesophageal reflux which commonly accompanies pulmonary fibrosis
  • Medications to address anxiety and depression

Managing Daily Life with Pulmonary Fibrosis

Treatment extends beyond medications and medical procedures to encompass the many ways people can take an active role in managing their condition day to day. These self-care measures can significantly impact quality of life.

Stopping smoking is absolutely critical for anyone with pulmonary fibrosis who still smokes. Tobacco smoke damages lungs further and can accelerate disease progression^[2]. Healthcare teams can provide support and resources to help people quit successfully.

Maintaining good general health through balanced nutrition, staying as active as possible within limitations, and getting recommended vaccinations helps prevent complications. Respiratory infections can be particularly serious for people with damaged lungs, so annual flu vaccines and pneumonia vaccines are strongly recommended^[19].

Managing other health conditions that often occur alongside pulmonary fibrosis is important. Gastroesophageal reflux disease (GERD), where stomach acid flows back into the esophagus, is very common in people with pulmonary fibrosis and may contribute to lung damage. Treatment for reflux through medications and lifestyle changes may be beneficial^[8].

Learning to recognize signs that the disease may be worsening allows for prompt medical attention. Increasing breathlessness, new or worsening cough, unintended weight loss, or episodes of sudden worsening called acute exacerbations all warrant immediate contact with healthcare providers^[22].

Regular follow-up with healthcare providers, typically including periodic pulmonary function tests and imaging studies, helps monitor disease progression and adjust treatment as needed. These appointments are opportunities to discuss concerns, address symptoms, and plan for the future^[11].